Turning discoveries into therapies
Here’s what’s in our Pipeline:
- Immuno-oncology CD200R1
- Immuno-oncology CD96
- Immuno-oncology *
- Cardiovascular / Metabolic*
*40+ programs in the combined therapeutic areas. As of March 31, 2021. Programs include collaborated, 100% owned and royalty interest targets.
Our current clinical programs
This 23andMe-owned immuno-oncology program is currently in Phase 1 in patients with advanced solid tumors (NCT05199272).
This immuno-oncology program with GSK is currently in Phase 1 in patients with advanced solid tumors (NCT04446351).